KXII Health Headlines

Unapproved device buys time for new pair of lungs

Posted: 07/02/2014 - PITTSBURGH (AP) - An Oklahoma man is slowly gaining strength at a Pittsburgh hospital with a second set of transplanted lungs in a procedure that was possible only through a device that until now hasn't been used in the U.S.

Warning signs and how to prevent a drowning

Updated: 06/19/2014 - DENISON, TX -- As the temperatures rise in Texoma, lifeguards and emergency crews are concerned about an increase in drowning accidents as more people hit the water.

FDA prepping long-awaited plan to reduce salt

Posted: 06/17/2014 - WASHINGTON (AP) - Food companies and restaurants could soon face government pressure to make their foods less salty - a long-awaited federal effort to try to prevent thousands of deaths each year from heart disease and stroke.

Safe Family: BB gun problems

Posted: 05/22/2014 - IOWA -- An Iowa woman is warning parents about the dangers of BB guns. She was hit in the chest and it is now lodged in her body. Vanessa Peng has her story in today's safe family report.
Video

Kids get codeine in ER despite risks, guidelines

Posted: 04/21/2014 - CHICAGO (AP) - Despite recommended limits on codeine use in children, the potent painkiller is prescribed for children in at least half a million emergency room visits each year, a study suggests.

Health overhaul signup ends, survives for now

Posted: 03/31/2014 - WASHINGTON (AP) - Monday marks the end of the six-month sign-up period for insurance under President Barack Obama's health care overhaul, a highly controversial attempt to reduce the number of Americans without medical coverage, estimated at about 50 million.

Study finds many preteens have high cholesterol

Posted: 03/28/2014 - There's fresh evidence that a lot of young people could be headed for heart trouble. A large study of preteens in Texas found that about one-third of them had borderline or high cholesterol when tested during routine physical exams.

More KXII Health Headlines

CBS News Health Headlines

WebMD Health News

AP Top Health Stories

  • Spain orders custody for parents of ill UK boy

    Ashya King parents's lawyer, Juan Isidro Fernandez Diaz, arrives at the National court in Madrid, Spain, Monday, Sept. 1, 2014. A critically-ill 5-year-old boy driven to Spain by his parents, Brett and Naghemeh, against doctors' advice is receiving medical treatment for a brain tumor in a Spanish hospital as his parents await extradition to Britain, police said Sunday. Officers received a phone call late Saturday from a hotel east of Malaga advising that a vehicle fitting the description circulated by police was on its premises. Both parents were arrested and the boy, Ashya King, was taken to a hospital, a Spanish police spokesman said. (AP Photo/Andres Kudacki)LONDON (AP) — The grandmother of a 5-year-old British boy with a severe brain tumor accused U.K. authorities on Monday of cruelty for seeking an arrest warrant and pursuing the family abroad after his parents removed him from a British hospital against medical advice.


  • India's Cipla launches copy of GSK's top asthma drug in Germany, Sweden
    India's Cipla Ltd has launched an anti-asthma inhaler in Germany and Sweden that is a generic version of GlaxoSmithKline Plc's Advair, a move that will further dent sales of the British firm's top-selling product. Cipla's drug will be marketed under the name Serrofloin in Germany and Salmeterol/Fluticasone Cipla in Sweden, the Mumbai-based company said in a statement on Monday. In December, Denmark became the first European country to approve for sale a generic version of GlaxoSmithKline's $8 billion-a-year Advair, and analysts have been expecting more such approvals.
  • Novartis Japan admits concealing drug side effects

    Swiss pharmaceuticals giant Novartis headquarter building is pictured on January 28, 2009 in BaselThe Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities. The revelations, which marked the latest in a string of scandals at the company's Japanese subsidiary, come after local authorities slapped the firm on the wrist, saying it had to clean up its operations. On Friday, Novartis issued a statement saying it had failed to report to regulators at least 2,579 cases where patients had suffered serious potential side effects from its drugs. Japan's Jiji Press news agency said they included some fatal cases, without specifying a figure.


  • Tests show no sign of Ebola in Swedish man

    Protective gear of Czech military personnel wearing protective gear hang on hooks in the Biological Defence Centre in the village of TechoninMedical authorities in the Swedish capital said on Monday tests on a man brought into hospital over the weekend and suspected of potentially carrying Ebola showed no signs the deadly disease. The Swedish man, whose name was not disclosed, had recently traveled to a "risk area" for the virus and had been taken to the Karolinska University Hospital in Stockholm suffering from a fever, sparking suspicions of Ebola. Stockholm county council said in a statement the man would continue to be treated at the hospital to ascertain the cause of his symptoms. More than 1,500 people have died in an Ebola outbreak in West Africa since March.


  • 'Most exciting ever' Novartis drug points to huge sales

    Logo of Swiss drugmaker Novartis is seen at its headquarters in BaselBy Ben Hirschler BARCELONA (Reuters) - Sales forecasts for Novartis's new heart failure drug are being ramped up by analysts after strikingly good clinical trial results for a medicine doctors expect to transform treatment of the deadly disease. David Epstein, Novartis' head of pharmaceuticals, said the launch of the drug next year promised to be the company's most exciting ever and profit margins on the medicine would be good. The results of a keenly-awaited clinical trial on LCZ696 were released at the annual meeting of the European Society of Cardiology on Saturday and published in the New England Journal of Medicine with a glowing editorial. Investigators working on the study and the company itself believe it has potential to replace drugs that have been central to treating heart failure for a quarter of century, opening up a multi-billion dollar sales opportunity.


Sherman 4201 Texoma Pkwy (903) 892 -8123 Ardmore 2624 S. Commerce (580) 223-0946
Gray Television, Inc. - Copyright © 2002-2014 - Designed by Gray Digital Media - Powered by Clickability